News
🇺🇸 AmericasLatest pharmaceutical news, drug approvals, and FDA regulatory updates
Latest News
Pharma Partnering US: $66B Deal Surge, Lilly & Sun Lead
Pharma dealmaking has surged to $66 billion as the Pharma Partnering Summit US 2026 gets underway. Sun Pharma is acquiring Organon for $11.75 billion, and Eli Lilly is acquiring Ajax Therapeutics for up to $2.3 billion.
Pharma Compliance Congress: Annex 1 Challenges & Solutions
PharmaCongress 2026 revealed that EU GMP Annex 1 compliance remains the pharmaceutical industry's dominant regulatory challenge, with widespread implementation gaps and inconsistent interpretations by inspection authorities. Collaborative partnerships and automated technical solutions are emerging as effective strategies to bridge compliance deficits.
COG 2024: Day 1 Highlights and Key Takeaways
NovaPharmaNews cannot publish Day 1 coverage of the 4th Annual COG conference due to unverified event details, absent clinical data, and lack of authoritative sources. Official confirmation and substantive research data are required.
Clinical Outsourcing Group Event: Key Takeaways Day 1
The Clinical Outsourcing Group event highlighted ongoing industry focus on CRO partnerships, technology integration, and regulatory expertise as pharmaceutical companies navigate complex clinical trial landscapes. While specific Day 1 presentations were not detailed in available coverage, clinical outsourcing remains a strategic priority for accelerating drug development timelines and managing operational costs.
Clinical Outsourcing Group: Key Takeaways for Pharma
The Clinical Outsourcing Group event highlighted strategic partnerships, regulatory compliance, and emerging technologies reshaping clinical trial management. Key takeaways for pharma: CRO selection now prioritizes regulatory expertise, decentralized trial capabilities, and real-world data integration.
ASCRS 2026: Opus Genetics' Phentolamine Eye Drop Data Preview
Opus Genetics will present Phase 3 data on phentolamine ophthalmic solution at the ASCRS Annual Meeting 2026, covering studies for presbyopia, post-refractive surgery vision impairment and mydriasis reversal.
FDLI 2026: FDA Leaders to Discuss Strategic Priorities
The 2026 FDLI Annual Conference will take place May 6-7, 2026, in Washington, DC, focusing on FDA strategic priorities and featuring sessions with FDA leaders. Attendees can expect discussions on AI in medical product development, FDA inspections, and networking opportunities.
COG 2024: Key Takeaways and Highlights from Day 1
The 2nd Annual COG 2024 conference lacked verified details from authoritative sources. NovaPharmaNews could not confirm the event's pharmaceutical focus, agenda, or clinical announcements without official documentation.
Clinical Outsourcing Group 2026: Key Takeaways and Highlights
A roundup of clinical trial data presented at recent medical conferences, including the Charing Cross Symposium, Heart Rhythm 2026, and ARVO 2026. No breaking news was reported from the Clinical Outsourcing Group 2026 event.
Cellenkos Receives FDA Clearance for CK0801 Phase 2 Trial in Aplastic Anemia
Cellenkos Inc. gets FDA approval to start Phase 2 trial of CK0801, an allogeneic cord blood-derived Treg therapy for transfusion-dependent aplastic anemia.
AstraZeneca's SAPHNELO Autoinjector Approved by FDA for Self-Administration in Lupus Treatment
FDA approves SAPHNELO Pen autoinjector for weekly self-administration in systemic lupus erythematosus, offering patients greater treatment convenience.
DMX-200 ACTION3 Trial Maintains Statistical Power Above 90% Following Blinded Data Review
External statistical review confirms DMX-200's ACTION3 trial remains >90% powered to demonstrate proteinuria reduction in kidney disease patients.
Concept Medical Presents 3-Year SIRONA Trial Data at Charing Cross Symposium 2026
Concept Medical Inc. announced preliminary 3-year SIRONA trial results at CX Symposium 2026, strengthening its position in peripheral drug-delivery technologies.
Intellia Therapeutics Submits FDA Application for Lonvo-Z, First CRISPR Gene Therapy for Hereditary Angioedema
Intellia initiates rolling BLA submission for lonvo-z, a potential one-time CRISPR treatment for hereditary angioedema, marking a breakthrough in gene therapy.
Cordis Launches SELUTION SLR Drug-Eluting Balloon in Japan for Peripheral Artery Disease Treatment
Cordis launches SELUTION SLR PTA Drug-Eluting Balloon in Japan, the first sirolimus-eluting balloon approved for peripheral artery disease treatment.
Tovecimig Shows 56% Reduction in Cancer Progression Risk in Biliary Tract Cancer Trial
Tovecimig bispecific antibody demonstrates statistically significant improvement in progression-free survival versus paclitaxel alone in Phase 2/3 trial.
Intellia Therapeutics Achieves First-Ever Positive Phase 3 Results for In Vivo Gene Editing with Lonvoguran Ziclumeran in Hereditary Angioedema
Intellia's lonvoguran ziclumeran becomes first in vivo gene editing therapy to succeed in Phase 3, offering potential one-time cure for hereditary angioedema patients.
Sagimet Biosciences Plans Phase 3 Denifanstat Trial for Acne Treatment in 2026
Sagimet Biosciences announces Phase 3 trial for denifanstat acne treatment starting H2 2026, while advancing TVB-3567 FASN inhibitor in Phase 1 studies.
Apollomics Advances Vebreltinib c-MET Inhibitor with Phase 2/3 IND Submission for NSCLC Treatment
Apollomics reports clinical progress for vebreltinib c-MET inhibitor, with over 600 patients dosed and Phase 2/3 IND submission planned for NSCLC combination therapy.
Aclaris Therapeutics ATI-052 Phase 1a Trial Results and ATI-2138 Lead Indication Update Set for April 28, 2026
Aclaris Therapeutics announces Phase 1a trial results for anti-TSLP/IL-4R bispecific antibody ATI-052 and lead indication selection for ITK/JAK3 inhibitor ATI-2138.